Research on growth hormone therapy in Prader-Willi syndrome started in 1981, and thanks to that reasearch and the families who participated in the studies, the U.S. Food & Drug Administration (FDA) approved growth hormone therapy for the treatment of Prader-Willi syndrome in June 2000. Since then those with the most experience and expertise in Prader-Willli syndrome consider the use of growth hormone therapy standard protocol which should be started as soon as possible after receiving a diagnosis of PWS.
Growth hormone therapy helps children reach a height closer to their true genetic potential; whereas absent growth hormone therapy most individuals with PWS have short stature.
Although obtaining a normal height was an original reason for using growth hormone, numerous other benefits have been discovered including a better lean muscle to fat ratio and increased energy (which allows for increased activity level which may mean calorie reduction doesn’t have to be as great).
Please read through the additional resources to assist you in deciding if growth hormone therapy is right for your child. We also strongly recommend that you order the Growth Hormone and Prader-Willi Syndrome booklet from Prader-Willi Syndrome Association – USA.
PWCF maintains online and in-person Support Groups for parents and professionals.
PWSA (USA) maintains several Facebook support groups.